Vilaprisan

Drug Profile

Vilaprisan

Alternative Names: BAY 1002670; S-PRAnt; S-PRM; sPRM

Latest Information Update: 17 Apr 2017

Price : $50

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Small molecules; Sulfones
  • Mechanism of Action Progesterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Endometriosis; Uterine leiomyoma

Most Recent Events

  • 17 Apr 2017 Bayer initiates a phase I trial in subjects with hepatic impairment and in Healthy volunteers in Germany (NCT03092999)
  • 31 Mar 2017 Bayer plans a phase I trial in subjects with hepatic impairment and in Healthy volunteers in Germany (NCT03092999)
  • 01 Nov 2016 Bayer initiates a phase I pharmacokinetics trial in Healthy volunteers Germany (PO) (NCT02975440)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top